Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19206393 | 0.79 | EPHX1 (0.39) | GAARAB9ACA12CA1CA2 | |
| SCHEMBL20739882 | 0.78 | EPHX1 (0.41) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL27496291 | 0.76 | CA1 (0.36) | KMT2ACCR2ALDH1A1CA12CA1 | |
| SCHEMBL23542737 | 0.73 | KDM4E (0.46) | KMT2AKDM4EALDH1A1NPSR1GAA | |
| SCHEMBL19206550 | 0.71 | KMT2A (0.43) | KMT2AKDM4EALDH1A1NPSR1GAA | |
| SCHEMBL2792237 | 0.70 | MCL1 (0.42) | KMT2AKDM4ECCR2GAARAB9A | |
| SCHEMBL1935629 | 0.70 | MCL1 (0.42) | KMT2AKDM4ECCR2GAARAB9A | |
| SCHEMBL12341655 | 0.70 | TSHR (0.36) | CCR2ALDH1A1GAATSHR | |
| SCHEMBL7255516 | 0.69 | KMT2A (0.53) | KMT2AKDM4EALDH1A1NPSR1GAA | |
| SCHEMBL4952777 | 0.69 | TSHR (0.56) | KMT2AKDM4EALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914273-B | [1,2,4] triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | 伊莱利利公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11401274-B2 | [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | ELI LILLY AND COMPANY (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3665174-B1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | LILLY CO ELI (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3414249-B1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3414249-B1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2021-05-20 | — | — | US | disclosed |
| EP-3665174-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | Eli Lilly and Company (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914273-A | [1,2,4] triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | 伊莱利利公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019032383-A1 | [1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY (US) | 2019-02-14 | — | — | WO | disclosed |
| EP-3414249-A1 | PDE1 INHIBITOR | Eli Lilly and Company (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10112951-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180099973-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099973-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-04-12 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| WO-2017139186-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139186-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112951-B2 | PDE1 inhibitor | PDE3B, PDE5A, PDE3A | KMT2A 1744/4885KDM4E 451/4885CCR2 1167/4885 |
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | PDE3B, PDE3A, PDE5A | KMT2A 2806/4885KDM4E 1220/4885CCR2 566/4885 |
| US-11401274-B2 | [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | PDE3B, PDE3A, PDE5A | KMT2A 2806/4885KDM4E 1220/4885CCR2 566/4885 |
| US-20180099973-A1 | PDE1 INHIBITOR | PDE3B, PDE5A, PDE3A | KMT2A 1744/4885KDM4E 451/4885CCR2 1167/4885 |
| US-20170233396-A1 | PDE1 INHIBITOR | PDE3B, PDE5A, PDE3A | KMT2A 1744/4885KDM4E 451/4885CCR2 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.